The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc,RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2. These findings suggest a common step in receptor-mediated signal transduction leading to exocytosis and transcription and imply that immunosuppressive drugs target specific signal transduction pathways, rather than specific cell types. This hypothesis is supported by studies on the effect of rapamycin on IL-3 dependent proliferation of the rodent mast cell line PT18. Rapamycin inhibits proliferation of PT18 cells, achieving a plateau of 80% inhibition at 1 nM. This inhibition is prevented in a competitive manner by FK506, a structural analogue of rapamycin. Proliferation of rat basophilic leukemia cells and WEHI-3 cells was also inhibited, at doses comparable to those shown previously to inhibit IL-2-dependent proliferation of cytotoxic T lymphocyte line (CTLL) cells. In contrast, proliferation of A-431 cells, a epidermoid cell line, was not affected by rapamycin. DNA histograms indicate that complexes formed between the rapamycin-FK506-binding protein (FKBP) and rapamycin arrest-proliferating
INTRODUCTION
The immunosuppressive drugs FK506 and rapamycin both bind to the FK506-binding proteins (FKBP) ,' a group of cytosolic proteins with peptidyl-prolyl cis-trans isomerase (PPlase) activity (Harding et al., 1989; Siekierka et al., 1989; Jin et al., 1991; Schreiber, 1991) . Whereas both drugs form stable complexes with FKBP and inhibit its intrinsic PPlase activity, only FKBP-FK506 complexes are inhibitory for multichain immune recognition receptor (MIRR)-signaling pathways [e.g., T cell receptor (TCR) or high-affinity IgE receptor (Fc,RI) ]. In contrast, FKBP-rapamycin complexes do not inhibit signaling from these receptors, and in fact rapamycin prevents the inhibition by FK506 (Bierer et al., 1990a,b; ' Hultsch et al., 1991) . On the other hand, FKBP-rapamycin complexes inhibit IL-2 receptor-mediated activation (proliferation) of cycotoxic T lymphocyte line (CTLL) cells, whereas FKBP-FK506 complexes are not inhibitory in this pathway (Bierer et al., 1990a,b) . These data are summarized in Table 1 Cell Culture PT18 cells, an IL-3-dependent mouse mast-cell line, was grown as described (Costa et al., 1992) . Briefly, RPMI 1640 was supplemented with 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 4 mM L-glutamine, 100,ug/ml penicillin, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 10% vol/vol heatinactivated fetal calf serum (FCS) (WEHI-medium). This medium did not support the growth of IL-3-dependent cells, and is therefore referred to as "cytokine free." WEHI+ medium was further supplemented with 10% (vol/vol) WEHI supematants (Biomedical Products, Bedford, MA). rIL-3 medium consists of WEHI-medium plus the indicated amount of rIL-3 (Genzyme, Boston, MA).
RBL-2H3 cells were maintained in 175-cm2 tissue culture flasks as described . RBL cells were maintained in adherent cultures in Eagle's minimal essential medium (EMEM) (cat. no. 100, Biofluids, Rockville, MD) supplemented with 16% FCS (Biofluids) and 3.3 mM L-glutamine. For serial passage and to prepare the cells for experiments, the cells were detached by incubation with trypsin-EDTA for 5-6 min at 37°C.
WEHI-3 cells and A-431 cells were obtained from American Type Culture Collection (ATCC) (cat. no. TIB 68 and CRL 1555, respectively) and were propagated according to the instructions of the provider. WEHI-3 cells were grown in the same medium as PT18 cells, except WEHI supematant was omitted. A-431 cells were propagated in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 10% heat-inactivated FCS, 100 U/ml Penicillin G, 100 ,g/ml Streptomycin, and 250 ng/ml Amphotericin B.
Proliferation Assays
Proliferation assays were performed essentially as described (Malone et al., 1988) . Cells were pelleted by centrifugation at 25°C for 5 min at 400 X g and washed twice in the appropriate medium. For the PT18 cell proliferation assay in rIL-3-conditioned medium, the cells were allowed to equilibrate for 3 h in unconditioned medium (containing no exogenous cytokines) before rIL-3 was added at the concentration indicated. Cells Flow Cytometry PT18 cells were washed and incubated in WEHI-medium for 3 h before being resuspended in 2 ng/ml rIL-3 medium. Aliquots of PT18 cells were taken at t = 0, 6, 12, 18, 24, 30 , and 40 h and were subjected to propidium iodine staining and flow cytometry as described (Costa et al., 1992 Hialeah, FL), and the percentage of cells in each cell cycle was calculated with the EPICS cytologic DNA package (Counter Electronics).
Presentation of Data
All proliferation assays were performed in triplicate, and all experiments were repeated at least three times. The results are expressed as the average ± SD of a representative experiment. Error bars are omitted where they fall within the size of the symbol.
RESULTS

Proliferation of PT18 Cells in rIL-3-Supplemented Medium
WEHI cell supematant, used to condition the PT18 cell medium, is routinely used as a source of IL-3 to propagate IL-3-dependent cell lines (Razin et al., 1984) . However, WEHI cell supernatant may contain growth factors other than IL-3, which are capable of influencing growth of mast cells (e.g., Gm-CSF). Because we wanted to study the effect of rapamycin on the IL-3 receptor signaling, PT18 cells were grown on rIL-3-conditioned medium. Before all experiments, PT18 cells were washed two times in WEHI-medium and incubated in this medium for 3 h. Thereafter the cells were resuspended in rIL-3-containing medium and allowed to proliferate for the indicated time period. Figure 1 shows a rIL-3 dose-response curve. To study the effect of rapamycin under conditions where the cells are most sensitive to the IL-3 receptor-mediated proliferative signals, it was decided to study the effect of rapamycin and FK506 at 2 ng/ml rIL-3. Rapamycin Inhibits Proliferation of rIL-3-Driven PT18 Cells. an IC50 of 0.1 nM. The magnitude of inhibition is dependent on the concentration of rIL-3 used. Whereas 1 nM rapamycin inhibits proliferation of PT18 cells by 80% at 2 ng/ml rIL-3 (Figure 2 ), at 20 ng/ml rIL-3, the inhibition plateaus at -50% (10 nM rapamycin). Addition of 10 nM FK506, which has no effect on prolif- (Trenn et al., 1989) . Moreover, Fc,RI-mediated cytokine transcription has been reported (Burd et al., 1989; Plaut et al., 1989; Wodnar-Filipowicz et al., 1989) . In any case, a given immunophilin ligand interfered with a given signaling pathway in the same manner, regardless of the activation parameter followed (exocytosis or transcription of cytokines). For references, see Elliott et al., 1984; Kronke et al., 1984; Bierer et al., 1990; Hohman and Hultsch, 1990; Hultsch et al., 1990 Hultsch et al., , 1991 De Paulis et al., 1991. Vol. 3, September 1992 eration itself, prevented the inhibitory effect of rapamycin at lower doses (Figure 3) . However, high doses of rapamycin overcame the FK506 effect, which is consistent with the affinity of the two drugs for FKBP (see Table 2 ). 
Rapamycin Inhibits Proliferation of RBL Cells
The RBL 2H3 cell line is a tumor analogue of rat mast cells derived from f-chlorethylamine-treated rats and is closely related to the mucosal type mast cell (Metzger et al., 1986; Oliver et al., 1988) . The 2H3 clone proliferates in the absence of exogenous cytokines. In these cells, Fc,RI-mediated degranulation is sensitive to FK506 (IC5o 2 nM) (Hultsch et al., 1991) . Interestingly, similar to what has been observed with the PT18 cells, rapamycin inhibited proliferation of RBL cells (Figure 4 ), whereas FK506 did not. The fact that higher concentrations of rapamycin were required in these experi- [3H]-thymidine (25 nCi/ml) was added and proliferation was measured either in the presence of 10 nM FK506 or 10 nM rapamycin, or none of the drugs, as described in MATERIALS AND METHODS. 320.
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160. and G2, 4.5%) showed a normal distribution of cells, the 5 nM rapamycin-treated cells accumulated in the GO/Gl-phase (B: GI, 81.6%; S, 15.3%; and G2, 3.1%). Ethanol, the solvent for rapamycin and FK506 had no effect in any of these assays.
Vol. 3, September 1992 mastocytoma cell line (Figure 2 ). FK506, a structural analogue of rapamycin that binds to the same intracellular binding protein FKBP, had no effect when used alone. However, used together with rapamycin, FK506 antagonized the inhibitory effect of rapamycin (Figure 3) . The anti-proliferative effect of rapamycin is not restricted to the IL-3-dependent PT18 cell line. RBL cells (a tumor cell line of the mucosal mast cell type) and WEHI-3 cells (a mouse myelo-monocytic cell line), both of which grow in the absence of added cytokines (other than those possibly contained in fetal calf serum), are also inhibited by rapamycin. This may be due to the fact that RBL cells and WEHI-3 cells synthesize and secret IL-3 (or other cytokines), which then binds to cytokine receptors in an autocrine loop. It is interesting that inhibition of proliferation of these cell lines by rapamycin plateaus at 30-40%, whereas PT18 cells, grown with 2 ng/ml rIL-3 exhibited a greater sensitivity. However, when PT18 cells were driven with WEHI cell supernatants or high rIL-3 concentrations, they were less sensitive to rapamycin treatment as well (40-50% inhibition with 10 nM rapamycin). Taken together, these results suggest that RBL cells and WEHI-3 cells were, in part, less sensitive to rapamycin because they synthesize large amounts of cytokines, which stimulates their cytokine receptors maximally.
All of the rapamycin-sensitive cells tested were marrow derived: mast cells (PT18 and RBL), WEHI-3 cells, and lymphocytes (Bierer et al., 1990a,b) . It is possible that the rapamycin sensitivity of lymphokine receptor (LKR)-mediated proliferation is a general phenomena of marrow-derived cells, which express cytokine receptor of a certain class (IL-2, IL-3, IL-4, or erythropoietin receptors (Itoh et al., 1990) . The finding that proliferation of epidermoid cells is not sensitive to rapamycin, plus the cell cycle distribution of PT18 cells after rapamycin treatment demonstrating accumulation of PT18 cells in the GO/Gl-phase, indicates that the target of inhibition by rapamycin is likely to be within the LKR signaling pathways or possibly at their link to cell cycle controlling mechanisms. The DNA histograms presented in Figure   7 demonstrate an arrest at the G1/S-border for the rapamycin-treated cells, suggesting that a hypothetical "G1/S-gate" is closed under these conditions. Only a small fraction of the PT18 cells could advance through this block, and this fraction does not increase substantially at later time points (<40 h). These results are consistent with a previous study, showing growth arrest of yeast cells in the G1-phase, as judged by their budding pattern (Heitman et al., 1991) .
It has been suggested that highly conserved mechanisms, involving the phosphorylation pattern of p34-cdc2/ p33-cdk2 and complex formation with cyclins, control progression through cell cycle and thereby proliferation (Murray and Kirschner, 1989; Nurse, 1990; Fang and Newport, 1991; Tsai et al., 1991 (anti-proliferative effect) has been shown recently to interfere with p34-cdc2/ p33-cdk2 phosphorylation, resulting in a growth arrest of cells in the late G1-phase (Howe et al., 1991) .
It is tempting to speculate that in IL-2/IL-3-dependent cell lines, a LKR-mediated signal modulates the phosphorylation pattern Of p34-cdc2mp33-cdk2 In this scenario, FKBP-rapamycin complexes may interfere with a LKR-dependent p 4-cdc2/p33-ca2 kinase or phosphatase.
In the light of the concept that the cell cycle is controlled by phosphorylation and dephosphorylation of p34-cdc2/ p33-cdk2 it is interesting that FKBP-FK506 complexes bind to and inhibit calcineurin, a serine/threonine phosphatase, in vitro (Liu et al., 1991) (Keegan and Paul, 1992) . In these experiments, the effect of FK506, but not the effect of CsA, was prevented by cotreatment with rapamycin (Bierer et al., 1990a,b; Wicker et al., 1990; De Paulis et al., 1991; Hultsch et al., 1991) .
In vitro binding studies with FK506, rapamycin, and CsA showed high-affinity binding of immunophilins to their respective ligands. The results with cyclophilin and FKBP (Handschumacher et al., 1984; Bierer et al., 1990a,b) have led to the conclusion that these drugs mediate their effects through complex formation with their respective intracellular receptor (Bierer et al., 1990a,b; Schreiber, 1991) . This is supported by the correlation between the Kd and IC50 for receptor-mediated signaling pathways (see Table 2 ) and applies also for the effect of rapamycin on IL-3 receptor-mediated proliferation of mast cells.
The use of the FKBP ligands FK506 and rapamycin to characterize receptor-mediated signaling pathways permits these pathways to be differentiated into three groups: 1) rapamycin-sensitive LKR pathways; 2) FK506-sensitive signal transduction pathways (including TCR, FcERI, and BCR); and 3) rapamycin/FK506-insensitive pathways, e.g., C5a and FMLP receptors (Forrest et al., 1991) . This functional classification in different receptor families is supported by structural data, indicating 60% sequence homology between the TCR zeta chain and the Fc,RI gamma chain, the proposed signaling subunits of the respective multichain receptors (Orloff et al., 1990) . In fact, chimeric receptors constructs fusing the extracellular and transmembrane domain of the IL-2 receptor alpha chain (tac) with cytoplasmic domain of the TCR-zeta chain induce exo-986 cytosis from RBL cells, when aggregated with anti-tac (Letourneur and Klausner, 1991) .
Cloning studies of LKR have suggested a distinct receptor gene family, consisting of IL-2-receptor beta chain, the IL-3, IL-4, and erythropoietin receptor (Itoh et al., 1990) . While not proving that these sequence homologies are functionally relevant, it is interesting that the sensitivity of a certain receptor type to a given immunophilin ligand correlates with the structurally defined receptor families.
The contrasting effects of FKBP-rapamycin and FKBP-FK506 complexes in MIRR and LKR signaling types, raises the question of whether rapamycin and FK506 mimic the effects of natural ligands of FKBP (Hultsch et al., 1991 (Hesketh et al., 1984; Oliver et al., 1988; Hultsch et al., 1990 Hultsch et al., , 1991 . In this scenario, FKBP-FK506-like complexes would support a "trophic state" of a cell, whereas FKBP-rapamycin-like complexes were suitable during the "effector state" of the cell cycle.
